查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1592779

Empox（猴痘）的全球市场的评估:各治疗类型，各给药途径，各流通管道，各地区，机会，预测(2017年～2031年)

Monkeypox (Mpox) Market Assessment, By Treatment Type, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 229 Pages | 商品交期: 3-5个工作天内

价格

全球 Empox（猴痘）市场规模预计将从 2023 年的 1.859 亿美元增长到 2031 年的 4.0816 亿美元，在 2024-2031 年预测期内的复合年增长率为 10.33%。由于 Mpox 盛行率不断上升、诊断技术的进步、公众健康意识的提高以及投资者对开发 Mpox 疫苗和治疗方法的兴趣日益浓厚，预计预测期内 Mpox 的市场需求将呈指数级增长。

Empox 是正痘病毒属的病毒感染，会引起皮疹、黏膜病变、发烧、头痛、肌肉痛、疲劳和淋巴结肿大等症状，持续 2 至 4 週。由于疫情爆发和公共卫生计划的实施，人们的认识不断提高，推动了对诊断、治疗和预防措施的需求。有效疫苗和监管部门批准的进步将进一步推动市场发展，而不断增加的疾病负担可能会在预测期内推动加速的疫苗接种运动推动市场向前发展。例如，2023 年 1 月，Becton, Dickinson and Company (BD) 和 Certest Biotec, SL 获得了美国食品药物管理局 (FDA) 对 VIASURE 猴痘病毒即时 PCR 试剂的紧急使用授权 (EUA)。该 EUA 将能够及时检测 Empox 并支持美国的疾病管制工作。

本报告提供全球 Empox（猴痘）市场相关调查分析，提供市场规模与预测，市场动态，主要企业的形势等资讯。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 摘要整理

第4章 全球 Empox（猴痘）市场预测(2017年～2031年)

  • 市场规模的分析与预测
    • 金额
  • 市场占有率的分析与预测
    • 各治疗类型
    • 各给药途径
    • 不同流通管道
    • 各地区
    • 市场占有率分析:各企业(金额)(前五名公司和其他 - 2023年)
  • 市场地图分析(2023年)
    • 各治疗类型
    • 各给药途径
    • 各流通管道
    • 各地区

第5章 北美的 Empox（猴痘）市场预测(2017年～2031年)

  • 市场规模的分析与预测
    • 金额
  • 市场占有率的分析与预测
    • 各治疗类型
    • 各给药途径
    • 不同流通管道
    • 占有率:各国
  • 各国的市场评估
    • 美国的 Empox（猴痘）市场预测(2017年～2031年)
    • 加拿大
    • 墨西哥

第6章 欧洲的 Empox（猴痘）市场预测(2017年～2031年)

  • 德国
  • 法国
  • 义大利
  • 英国
  • 俄罗斯
  • 荷兰
  • 西班牙
  • 波兰

第7章 亚太地区的 Empox（猴痘）市场预测(2017年～2031年)

  • 印度
  • 中国
  • 日本
  • 澳洲
  • 越南
  • 韩国
  • 印尼
  • 菲律宾

第8章 南美的 Empox（猴痘）市场预测(2017年～2031年)

  • 巴西
  • 阿根廷

第9章 中东·非洲的 Empox（猴痘）市场预测(2017年～2031年)

  • 沙乌地阿拉伯
  • 阿拉伯联合大公国
  • 南非
  • 以色列

第10章 价值链分析

第11章 流行病学概要

第12章 波特的五力分析

第13章 大环境分析

第14章 价格分析

第15章 市场动态

  • 推动市场要素
  • 市场课题

第16章 市场趋势与发展

第17章 法规结构和革新

  • 临床试验
  • 法规当局的认证

第18章 专利形势

第19章 案例研究

第20章 竞争情形

  • 前五名市场领导者的竞争矩阵
  • 前五名公司的SWOT分析
  • 前十大主要企业的形势
    • Bavarian Nordic A/S
    • Emergent BioSolutions Inc.
    • SIGA Technologies Inc.
    • Chimerix Inc.
    • Piramal Enterprises Ltd.
    • Gilead Sciences, Inc.
    • KM Biologics Co.
    • Jiangsu BioPerfectus Technologies Co., Ltd
    • Hangzhou Testsea Biotechnology Co., Ltd.
    • Quest Diagnostics Incorporated.

第21章 策略性推荐

第22章 本公司相关资料，免责声明

Product Code: MX12227

Global monkeypox (Mpox) market is projected to witness a CAGR of 10.33% during the forecast period 2024-2031, growing from USD 185.90 million in 2023 to USD 408.16 million in 2031. The market demand for Mpox is anticipated to thrive drastically in the forecast years due to the rising prevalence of monkeypox disease, advancement in diagnostic technology, public health awareness, and the growing interest of investors in the development of monkeypox vaccines and therapeutics.

Mpox is a viral infection within the Orthopoxvirus genus, causing symptoms such as skin rash, mucosal lesions, fever, headache, muscle pain, fatigue, and swelling of the lymph nodes that last for two to four weeks. Growing awareness due to outbreaks and public health programs has increased demand for diagnostics, therapeutics, and preventive measures. Advances and regulatory approvals of effective vaccines further spur the market, and accelerated vaccine campaigns are foreseen to propel the market ahead in the forecast period due to the increasing disease burden. For instance, in January 2023, Becton, Dickinson and Company (BD) and Certest Biotec, S.L. received an Emergency Use Authorization (EUA) approval from the U.S. Food and Drug Administration (FDA) for the VIASURE Monkeypox Virus Real-Time polymerase chain reaction (PCR) reagent. The EUA allows for timely Mpox detection, supporting disease control efforts in the United States.

Increase in the Incidences of Monkeypox (Mpox) Disease

The incidence of monkeypox disease has become a terrific public health concern because recent outbreaks have occurred in areas other than the traditional endemic zones. Initially restricted to Central and West Africa, this infection has seen a rise in cases worldwide, partially due to increased human-animal contact, environmental changes, and world travel. The sharp rise in infections has incited health authorities to heighten vigilance and response efforts, thereby creating public awareness and a sense of urgency over the disease. It places an increased demand for appropriate diagnostics, vaccines, and treatments as a robust public health strategy is paramount in managing and mitigating monkeypox. This new epidemiology requires preparation in how one responds to emerging infectious diseases in an increasingly interconnected world. For instance, in August 2024, UTime Limited completed the acquisition of the Bowen Therapeutics laboratory of Bowen Therapeutics Inc. at UMASS Medical School to cater to the need for an effective monkeypox vaccine. Monkeypox, as such, is an infectious disease caused by the monkeypox virus.

Demand for Vaccines and Treatment for Monkeypox Disease to Drive Market Growth

The rising demand for vaccines and new treatments for monkeypox is mainly driven by increased awareness that the virus could spread more widely than people thought, posing risks to public health. This awareness encourages more research and development to find effective ways to prevent and treat the disease. The recent outbreaks highlighted the need for proper preventive measures and resulted in vaccination programs at governmental and health organizations. This growing urgency drives pharmaceutical companies, researchers, and public health officials to collaborate and perform research and developmental activities to deliver novel products. In general, the focus is on the accessibility of vaccines, alternatives for treatment, infection control, and preparing the world to face emerging infectious diseases with a proactive attitude toward public health challenges. In August 2024, the World Health Organization (WHO) declared Mpox as a public health emergency of international concern due to an upsurge of Mpox cases in the Democratic Republic of the Congo (DRC). To effectively tackle this situation, the United Nations International Children's Emergency Fund (UNICEF) signed an agreement with Bavarian Nordic A/S, under which the MVA-BN Mpox vaccine would be made available to 77 low and lower-middle-income countries at the lowest price in the market. Moreover, in September 2024, WHO initiated funding of USD 58.8 million to deliver treatment for controlling the outbreak of Mpox in Burundi, Central African Republic (CAR), DRC, Kenya, Rwanda, and Uganda. These countries have registered around 22,000 cases, with around 60% cases among children under 15 years old and 80% deaths among children.

North America to Dominate Monkeypox (Mpox) Market Share

North America leads the share of the monkeypox market due to several interrelated factors, such as enhanced treatment accessibility, innovation, and new product launches. According to data from the US Centers for Disease Control and Prevention, Mpox cases in the United States have surged to a rate of 511 reported cases, showing a significant increase from 300 thousand cases by March 2023. While current transmission rates remain substantially lower than the tens of thousands reported in 2022, experts warned of potential case increases due to several factors. The expiration of the public health emergency over a year ago has limited federal resources for managing the response.

Additionally, the relatively low vaccination coverage continues to leave a substantial portion of the population at risk, underscoring the urgent need to improve vaccination efforts as transmission risks rise. In April 2024, Bavarian Nordic A/S launched JYNNEOS in the United States, the only FDA-approved Mpox vaccine. The launch has marked a significant expansion of the company's activities in the highly promising North American market. Moreover, growing awareness about vaccination and the rising target patient population will further fuel the adoption of JYNNEOS in the United States. According to the data published by the Centers for Disease Control and Prevention (CDC), around two million individuals in the United States are considered eligible for vaccination against Mpox in 2024. The data further stated that 60% of this population remains completely unvaccinated, and 15% have received just one dose of the vaccine. Real-world data demonstrate protective immunity to be more robust in vaccinated individuals who received the primary series of two doses, as indicated by the CDC, than in unvaccinated or one-dose recipients.

Future Market Scenario (2024-2031F)

The future market scenario is influenced by factors that increase demand and investment, such as the growing awareness about infectious diseases. Healthcare systems are gaining a focus on preparedness for outbreaks through increased funding for research, diagnostics, and vaccines. The recent outbreaks have forced the regulatory bodies to hasten their approval processes for monkeypox treatments and vaccines, boosting market dynamics. Several studies that are undergoing clinical trials, for instance, a phase 3 study of Tecovirimat for the Mpox virus, conducted by the National Institute of Allergy and Infectious Diseases (NIAID) to assess the efficacy of Tecovirimat for the treatment of human Mpox virus disease is holding promising outcomes. Moreover, an ongoing safety study of the MVA-BN Vaccine among children between 2-12 years is being conducted by Bavarian Nordic A/S. The study aims to compare the immunogenicity and safety of the MVA-BN vaccine to prevent Mpox, Smallpox, and other Orthopoxvirus Infections. The promising outcomes from such ongoing trials are expected to expand the existing patient base and introduce newer treatment lines, boosting market growth in the forecast years.

Key Players Landscape and Outlook

Monkeypox (Mpox) market is highly dynamic, with different players such as Bavarian Nordic A/S, Emergent BioSolutions Inc., and others. Market activity in recent years includes business agreements, collaborations, and regulatory approvals of products. The market fosters several smaller players, collaborating with other players to cater to a larger market.

In September 2022, Emergent BioSolutions Inc. (Emergent) acquired global rights of Tembexa, an oral antiviral treatment for smallpox, from Chimerix, Inc. This acquisition expanded Emergent product offerings and positioned the company alongside Siga Technologies Inc.'s Tpoxx as a potential treatment for monkeypox. The U.S. Biomedical Advanced Research and Development Authority supported the deal, signing a USD 680 million contract and securing 1.7 million Tembexa courses over 10 years.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Monkeypox (Mpox) Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Treatment type
      • 4.2.1.1. Vaccines
        • 4.2.1.1.1. JYNNEOS
        • 4.2.1.1.2. ACAM2000
      • 4.2.1.2. Therapeutic
        • 4.2.1.2.1. Tecovirimat
        • 4.2.1.2.2. Brincidofovir
        • 4.2.1.2.3. Cidofovir
    • 4.2.2. By Route of Administration
      • 4.2.2.1. Oral
      • 4.2.2.2. Injectable
    • 4.2.3. By Distribution
      • 4.2.3.1. Hospital Pharmacies
      • 4.2.3.2. Retail Pharmacies
      • 4.2.3.3. Online Pharmacies
      • 4.2.3.4. Others
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia-Pacific
      • 4.2.4.4. South America
      • 4.2.4.5. Middle East and Africa
    • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Treatment Type
    • 4.3.2. By Route of Administration
    • 4.3.3. By Distribution Channel
    • 4.3.4. By Region

5. North America Monkeypox (Mpox) Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Treatment Type
      • 5.2.1.1. Vaccines
        • 5.2.1.1.1. JYNNEOS
        • 5.2.1.1.2. ACAM2000
      • 5.2.1.2. Therapeutics
        • 5.2.1.2.1. Tecovirimat
        • 5.2.1.2.2. Brincidofovir
        • 5.2.1.2.3. Cidofovir
    • 5.2.2. By Route of Administration
      • 5.2.2.1. Oral
      • 5.2.2.2. Injectable
    • 5.2.3. By Distribution
      • 5.2.3.1. Hospital Pharmacies
      • 5.2.3.2. Retail Pharmacies
      • 5.2.3.3. Online Pharmacies
      • 5.2.3.4. Others
    • 5.2.4. By Country Share
      • 5.2.4.1. United States
      • 5.2.4.2. Canada
      • 5.2.4.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Monkeypox (Mpox) Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Treatment Type
          • 5.3.1.2.1.1. Vaccines
          • 5.3.1.2.1.1.1. JYNNEOS
          • 5.3.1.2.1.1.2. ACAM2000
          • 5.3.1.2.1.2. Therapeutics
          • 5.3.1.2.1.2.1. Tecovirimat
          • 5.3.1.2.1.2.2. Brincidofovir
          • 5.3.1.2.1.2.3. Cidofovir
        • 5.3.1.2.2. By Route of Administration
          • 5.3.1.2.2.1. Oral
          • 5.3.1.2.2.2. Injectable
        • 5.3.1.2.3. By Distribution
          • 5.3.1.2.3.1. Hospitals Pharmacies
          • 5.3.1.2.3.2. Retail Pharmacies
          • 5.3.1.2.3.3. Online Pharmacies
          • 5.3.1.2.3.4. Others
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Monkeypox (Mpox) Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Monkeypox (Mpox) Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Monkeypox (Mpox) Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Monkeypox (Mpox) Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Value Chain Analysis

11. Epidemiology Overview

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

  • 17.1. Clinical Trials
  • 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Bavarian Nordic A/S
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 20.3.2. Emergent BioSolutions Inc.
    • 20.3.3. SIGA Technologies Inc.
    • 20.3.4. Chimerix Inc.
    • 20.3.5. Piramal Enterprises Ltd.
    • 20.3.6. Gilead Sciences, Inc.
    • 20.3.7. KM Biologics Co.
    • 20.3.8. Jiangsu BioPerfectus Technologies Co., Ltd
    • 20.3.9. Hangzhou Testsea Biotechnology Co., Ltd.,
    • 20.3.10. Quest Diagnostics Incorporated.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 2. Global Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 3. Global Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 4. Global Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 5. Global Monkeypox (Mpox) Market Share (%), By Region, 2017-2031F
  • Figure 6. North America Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 7. North America Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 8. North America Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 9. North America Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 10. North America Monkeypox (Mpox) Market Share (%), By Country, 2017-2031F
  • Figure 11. United States Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 12. United States Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 13. United States Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 14. United States Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 15. Canada Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 16. Canada Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 17. Canada Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 18. Canada Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 19. Mexico Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 20. Mexico Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 21. Mexico Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 22. Mexico Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 23. Europe Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 24. Europe Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 25. Europe Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 26. Europe Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 27. Europe Monkeypox (Mpox) Market Share (%), By Country, 2017-2031F
  • Figure 28. Germany Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 29. Germany Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 30. Germany Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 31. Germany Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 32. France Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 33. France Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 34. France Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 35. France Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 36. Italy Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 37. Italy Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 38. Italy Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 39. Italy Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 40. United Kingdom Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 41. United Kingdom Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 42. United Kingdom Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 43. United Kingdom Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 44. Russia Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 45. Russia Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 46. Russia Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 47. Russia Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 48. Netherlands Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 49. Netherlands Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 50. Netherlands Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 51. Netherlands Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 52. Spain Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 53. Spain Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 54. Spain Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 55. Spain Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 56. Turkey Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 57. Turkey Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 58. Turkey Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 59. Turkey Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 60. Poland Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 61. Poland Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 62. Poland Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 63. Poland Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 64. South America Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 65. South America Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 66. South America Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 67. South America Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 68. South America Monkeypox (Mpox) Market Share (%), By Country, 2017-2031F
  • Figure 69. Brazil Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 70. Brazil Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 71. Brazil Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 72. Brazil Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 73. Argentina Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 74. Argentina Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 75. Argentina Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 76. Argentina Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 77. Asia-Pacific Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 78. Asia-Pacific Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 79. Asia-Pacific Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 80. Asia-Pacific Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 81. Asia-Pacific Monkeypox (Mpox) Market Share (%), By Country, 2017-2031F
  • Figure 82. India Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 83. India Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 84. India Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 85. India Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 86. China Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 87. China Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 88. China Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 89. China Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 90. Japan Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 91. Japan Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 92. Japan Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 93. Japan Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 94. Australia Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 95. Australia Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 96. Australia Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 97. Australia Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 98. Vietnam Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 99. Vietnam Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 100. Vietnam Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 101. Vietnam Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 102. South Korea Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 103. South Korea Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 104. South Korea Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 105. South Korea Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 106. Indonesia Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 107. Indonesia Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 108. Indonesia Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 109. Indonesia Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 110. Philippines Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 111. Philippines Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 112. Philippines Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 113. Philippines Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 114. Middle East & Africa Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 115. Middle East & Africa Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 116. Middle East & Africa Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 117. Middle East & Africa Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 118. Middle East & Africa Monkeypox (Mpox) Market Share (%), By Country, 2017-2031F
  • Figure 119. Saudi Arabia Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 120. Saudi Arabia Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 121. Saudi Arabia Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 122. Saudi Arabia Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 123. UAE Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 124. UAE Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 125. UAE Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 126. UAE Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 127. South Africa Monkeypox (Mpox) Market, By Value, In USD Million, 2017-2031F
  • Figure 128. South Africa Monkeypox (Mpox) Market Share (%), By Treatment Type, 2017-2031F
  • Figure 129. South Africa Monkeypox (Mpox) Market Share (%), By Route of Administration, 2017-2031F
  • Figure 130. South Africa Monkeypox (Mpox) Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 131. By Treatment Type Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 132. By Route of Administration Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 133. By Distribution Channel Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 134. By Region Map-Market Size (USD Million) & Growth Rate (%), 2023